ACCELERATE YOUR COVID-19 RESEARCH WITH OUR PRODUCTS CATALOG

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019 nCoV (2019 Novel Coronavirus) represents a pandemic threat that has been declared a public health emergency of international concern by WHO, mobilizing the actors of all the fields to find new means to fight against this virus, in particular in the field of research.

Covalab is making all the effort to help you in your research by offering wide range of tools such as specific proteins from SARS-Cov-2, antibodies or immunoassays involved in the metabolic pathways of infection, to accelerate the research, diagnostic and treatment of COVID-19.

2019 nCoV is an enveloped, single, and positive-stranded RNA virus. The virus encodes four major structural proteins that have played important roles in causing the infection (*): Spike protein (S protein), nucleocapsid protein (N protein), membrane protein (M protein), and small envelope protein (E protein) (Fig.1).

*: Fehr, A.R. & Perlman, S. 2015. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282, 1-23

S protein is a large type I transmembrane protein, composed of two sub-units S1 and S2. S protein is essential for both host specificity and viral infectivity.

For viral entry, the S1 sub-unit binds via its RBD (Receptor Binding Domain) to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and after cleavage by proteases (Furin and TMPRSS2), the active S2 sub-unit fuses to the viral membranes with the host cell membrane. The spike protein is reported to induce the neutralizing-antibody and T-cell responses, as well as protective immunity. The CoV spike (S) glycoprotein therefore represent the key target for vaccines, therapeutic antibodies, and diagnostics (*).

*: Hoffmann, M. et al. 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell

SARS-Cov-2 can be triggered to fuse at either the plasma membrane or the endosomal membrane, and the route of entry is dependent on protease availability (Fig. 2).

The virus antigens are presented to the immune-system (APCs, macrophage, …) which in turn produce a range of pro- inflammatory "cytokines” (e.g. IL6, IFNα, IFNβ, IFNγ, IFNλ…) and TNF-α (*). In some cases, these cytokines proliferate and activate an uncontrolled and devastating pro-inflammatory response in the host.

* : Guo, Y.R. et al. 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 7, 11

Coronavirus Research Products:

For all information about these following products, contact us at enquiries@covalab.com

RECOMBINANT PROTEINS:

ANTIBODIES:

IMMUNOASSAYS:

PEPTIDES:

Thanks to our expertise in the fields of peptide design, synthesis and modification, we provide a high-quality peptide synthesis service, including a wide range of chemical modifications.

In addition, we offer a specific peptide library for research on SARS-CoV-2 form crude, >70% to very hight purity (>98%).

Contact us for design and more information about peptide synthesis at enquiries@covalab.com.

All our team are available for all requests.